The Buyer Report - Daniel Tepper

While cancer immunotherapies have been promising, CAR T cell therapies have been costly, effective on less than half of patients, and focused on hematologic cancers. Cytovia Therapeutics is enlisting natural killer cells, part of the innate immune system, to develop off-the-shelf immunotherapies to treat liquid and solid tumors. The company is leveraging a cluster of technologies to produce CAR NK cell therapies, edited NK cells to enhance their targeting, and NK engagers to redirect NK cells toward tumor targets. We spoke to Daniel Teper, co-founder and CEO of Cytovia, about the case for NK immunotherapies, Cytovia’s platform technologies, and the company’s pipeline of therapies in preclinical development.